October 16th 2024
Investigators sought to test the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention on levels of HbA1c.
Efficacy of Teplizumab in Clinical Trials
Egils K. Bogdanovics, MD, and the expert panel review the TN10 study data on the efficacy of teplizumab in delaying the progression of T1D, which led to the drug’s approval from the FDA.
Lower IQ scores associated with diabetic ketoacidosis in young type 1 diabetes patients
August 11th 2023Results of the randomized, multi-site study demonstrated the importance of early diabetes detection, as a single episode of diabetic ketoacidosis (DKA) in young children with type 1 diabetes was associated with lower IQ scores soon after exposure.
Interpreting T1D Antibody Test Results
Egils K. Bogdanovics, MD, and Schafer Boeder, MD, discuss interpreting antibody test results for type 1 diabetes and provide recommendations for retesting for those who have a negative test or have only 1 antibody present.
Clinical Signs Leading to Diagnostic Testing for T1D
Expert endocrinologists discuss the clinical symptoms that prompt testing for T1D, as well the diagnostic testing tools that are available in clinical practice.
Study: COVID-19 diagnosis associated with increased incidence of type 1 diabetes
July 28th 2023Further studies are needed to determine if vaccination should be considered in children at risk for type 1 diabetes (T1D), as a COVID-19 diagnosis among children was associated with an increased incidence of T1D, according to a recent study.
Rise in pediatric diabetes cases continued through year 2 of COVID-19 pandemic
July 20th 2023A follow-up to an earlier study, the latest research leveraged EHR data from medical centers in North Carolina and concluded incident cases of type 1 diabetes increased nearly 50% and incident cases of type 2 diabetes more than doubled in 2021-2022 relative to prepandemic years.
Study evaluates system for pediatric T1D management compliance
July 11th 2023To help teens with the difficult emotional and physical weight of managing this disease, numerous tools, technology platforms, and interventions have been developed. A research team recently published a review of one of these tools, a 40-year-old automated messaging system.
FDA approves empagliflozin, empagliflozin plus metformin for pediatric type 2 diabetes
June 21st 2023Children 10 years and older with type 2 diabetes (T2D) can now be treated with empagliflozin and empagliflozin plus metformin hydrochloride to improve blood sugar control, per a recent approval by the FDA.
Diabetes risk perception not associated with greater risk-reducing behaviors
June 13th 2023Intensive lifestyle change remains the primary treatment for youth-onset type 2 diabetes. According to a study in Jama Network Open, there is more work to be done as risk perception and awareness of diabetes alone were not associated with risk-reducing behaviors.
Acute and chronic complications in children with type 1 diabetes mellitus
June 1st 2023Part of the risk of developing kidney involvement begins when type 1 diabetes mellitus (T1DM) sets in and establishes itself in the patient, with up to 65% of children experiencing acute kidney injury during T1DM onset, which can further predispose to the development of future chronic kidney disease.
FDA clears algorithm-based automated insulin dosing system for T1D patients 6 years and up
May 25th 2023The Beta Bionics iLet ACE Pump and the iLet Dosing Decision software, matched with a compatible FDA-cleared integrated continuous glucose monitor, use an algorithm to determine and command insulin delivery to users.
Glucose levels are in target range at higher percentage with hybrid closed-loop system
May 16th 2023A hybrid closed-loop system can deliver glucose levels in the target range at a higher percentage of time among children aged 2 years to younger than 6 years compared to standard-care, according to a study in the New England Journal of Medicine.
Equitable access to glucose monitoring improves HbA1c levels
May 8th 2023Hemoglobin A1c improved in youths with newly diagnosed type 1 diabetes (T1D) when inclusive continuous glucose monitoring (CGM) was initiated, irrespective of ethnicity or insurance status. According to a study published in Jama Network Open, universal CGM could play a role in reducing disparities for minoritized racial and ethnic groups.
How insulin changed the way type 1 diabetes was treated in children
April 14th 2023Andrew Lam, MD, retinal surgeon, author, assistant professor, University of Massachusetts Medical School discusses the earliest treatments for type 1 diabetes in children, a topic of his new book, "The Masters of Medicine: Our Greatest Triumphs in the Race to Cure Humanity’s Deadliest Diseases," due out April 18, 2023.